Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stake: Amikacin in MDR-TB
NCT05555303Phase 2Recruiting
- Sponsor
- Rwanda Biomedical Centre
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amikacin in Tuberculosis (TB), sponsored by Rwanda Biomedical Centre. Started Mar 2023; status: recruiting.
02
Drugs
amikacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05555303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555303.